Back | Next |
home / stock / rvxcf / rvxcf message board
Subject | By | Source | When |
---|---|---|---|
Thanks. Time will tell. | big orange | investorshub | 12/01/2019 6:59:04 PM |
Shop themselves to anyone with cash? If | noretreat | investorshub | 12/01/2019 11:41:51 AM |
Any ideas what their plans are for the | big orange | investorshub | 12/01/2019 2:29:10 AM |
Not good. Here's hoping somebody buys them out. | big orange | investorshub | 11/19/2019 1:43:34 AM |
They missed their primary endpoint and have to | noretreat | investorshub | 11/19/2019 1:02:29 AM |
Then why did the bottom fall out? | big orange | investorshub | 11/19/2019 12:18:23 AM |
from another board | noretreat | investorshub | 11/18/2019 9:49:23 PM |
My concern is that there will need to | big orange | investorshub | 11/02/2019 4:35:12 PM |
I fully expect all remaining data on endpoints | noretreat | investorshub | 10/30/2019 10:40:33 AM |
NR, so are you all out of RVX,... | cabel | investorshub | 10/27/2019 11:09:34 PM |
Why should any of the rumors be true? | noretreat | investorshub | 10/26/2019 11:46:17 PM |
Shorting onto news? | noretreat | investorshub | 10/26/2019 11:44:59 PM |
My concern with the dramatic drop in pps | big orange | investorshub | 10/25/2019 6:54:47 PM |
I am more looking forward to hearing about | cabel | investorshub | 10/25/2019 4:24:10 PM |
arfxf All the rumors of "just missed it" and | noretreat | investorshub | 10/25/2019 4:09:39 PM |
NR, While we are waiting for more Data | cabel | investorshub | 10/25/2019 3:14:08 PM |
And the FDA did agree to the protocol. | noretreat | investorshub | 10/12/2019 5:32:12 PM |
Don't know what the protocol was for what | big orange | investorshub | 10/12/2019 5:08:52 PM |
not making any big bets on it, but | noretreat | investorshub | 10/10/2019 8:03:01 PM |
Hope you are right | big orange | investorshub | 10/10/2019 1:23:35 PM |
News, Short Squeeze, Breakout and More Instantly...
Calgary, Alberta--(Newsfile Corp. - May 13, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a two-year extension of the Company's US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of a...
2024-03-27 17:08:02 ET Developing safe, epigenetic therapeutics for people suffering from chronic illnesses Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions...
2024-03-27 17:08:02 ET The future of drug development Resverlogix is committed to developing epigenetic therapies for the benefit of patients with chronic disease. Their current clinical program focuses on advancing their lead compound ( apabetalone) and evaluating its th...